The Effects of Thiazolidinedione Therapy on NT-proBNP Levels in Patients with Type 2 Diabetes

D Hugh; Aydin CM; Billington E; Ignaszewski AP; Strelzow JA; Wise SJ; Yu E; Bondy GP

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

The Effects of Thiazolidinedione Therapy on NT-proBNP Levels in Patients with Type 2 Diabetes

Author(s):

D Hugh^{1, 2,*},

Aydin CM¹,

Billington E¹,

Ignaszewski AP^{1, 2},

Strelzow JA¹,

Wise SJ²,

Yu E^{1, 3},

Bondy GP^{1, 2}

1St. Paul’s Hospital

2University of British Columbia

3Center for Health Evaluation and Outcome Sciences, Vancouver BC, Canada

International Journal of Endocrinology and Metabolism:Vol. 6, issue 2; e94617

Published online:Jan 06, 2008

Article type:Research Article

Received:Mar 14, 2020

Accepted:Jan 06, 2008

How to Cite:D HughAydin CMBillington EIgnaszewski APStrelzow JAWise SJYu EBondy GPet al.The Effects of Thiazolidinedione Therapy on NT-proBNP Levels in Patients with Type 2 Diabetes.Int J Endocrinol Metab.6(2):e94617.

Abstract

We sought to determine whether thiazolidinedione (TZD) therapy affects levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with type 2 diabetes. Materials and Methods : This study population consisted of 76 patients with type 2 diabetes and no history of heart failure. Subjects had NTproBNP levels determined prior to initiating TZD therapy, and after 3 months of treatment. We compared within-person changes in NTproBNP over the 3 month duration. We determined if the magnitude of change in NTproBNP over the treatment period was correlated with baseline parameters or nature/dose of TZD medication. Results : The subjects were 42% female and 58% male, and the mean age and duration was 59.8±11.8 years old and 11.4±8.3 years respectively. The baseline mean A1C and BMI was 8.7±1.1% and 30.9±8.7 kg/m 2 respectively. We found that NT-proBNP levels did not vary significantly between baseline (mean±SD: 143.8±203.9 pg/mL) and 3 month follow-up (150.6±186.2 pg/mL). Conversely, A1C levels declined significantly (p<0.0001) and BMI increased significantly (p< 0.05). Conclusion : Adding TZD therapy to patients with type 2 diabetes and no history of heart failure does not have a significant effect on NTproBNP levels.

Keywords

Thiazolidinedione

NT-proBNP

Type 2 Diabetes

Congestive heart failure

Fulltext

The content of the article can be found in the PDF file.

References

1.
References are available in the PDF file.

comments